Metroplex-based Caris Life Sciences is launching a new early detection blood-based pan-cancer test. The first-in-class liquid biopsy platform will be capable of detecting stage 1 and stage 2 cancer by identifying mutations in blood with high concordance to tissue testing. The test is designed to be usable across different modalities, including therapy selection, monitoring of disease progression, detection of minimal residual disease and screening for early stage cancer.

President and Chief Scientific Officer David Spetzler says, “This funding [$890 million in growth equity] helps us to accelerate the advancement of our mission. We plan to use the capital to fund the commercialization of our innovative products, continue the development of bioinformatics and AI capabilities, expand our lab footprint and enhance our clinical and commercial organizations.”

Caris asserts that the combination approach is the most comprehensive and clinically relevant profiling available on the market. “Our technology unlocks the full potential of precision medicine through a more comprehensive interrogation of cancer at the molecular level,” says Spetzler.

For more information, visit CarisLifeSciences.com.